Viking Therapeutics Gains as Major Indexes Show Mixed Moves

Viking Therapeutics closed at $32.74, up 2.92% from the previous session. The S&P 500 fell 0.25%, the Dow lost 0.86%, and the Nasdaq gained 0.24%.

Over the previous month, the shares fell 5.52%. That decline was steeper than the medical sector’s 1.01% loss and the S&P 500’s 0.42% drop.

Investors are awaiting Viking’s next financial results. Zacks projects a loss of $1 per share, which would be a 23.46% decline from the year-earlier period.

For the full fiscal year, Zacks consensus estimates call for a loss of $4.47 per share and revenue of $0 million. Those figures represent changes of -40.13% and 0%, respectively, from the prior year.

Zacks said the consensus earnings-per-share estimate has not changed over the past month. The projections are estimates, not reported results.